FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
Publishing timestamp: 2024-05-31 13:03:49
Summary
The FDA approved Moderna's vaccine for respiratory syncytial virus, providing the company with a much-needed revenue source. The approval is based on a late-stage trial on older adults, and the vaccine will be marketed under the brand name mRESVIA. Moderna's mRNA platform is being used to tackle a range of different diseases beyond Covid. Investors have high hopes for the company's mRNA product pipeline, with shares up more than 60% this year.
Sentiment: POSITIVE
Tickers: PFE, MRNA, GSK-GB, GSK,
Keywords: business news, pfizer inc, biotech and pharmaceuticals, breaking news, stéphane bancel, breaking news: business, science, biotechnology, pharmaceuticals, health care industry, united states, business, moderna inc, gsk plc,
Source: https://www.cnbc.com/2024/05/31/fda-approves-moderna-rsv-vaccine-for-seniors.html